Charcot–Marie–Tooth disease (CMT) is a group of inherited disorders of the peripheral nervous system characterized by slowly progressive muscle weakness and wasting, reduced sensation, and diminished tendon reflexes. The longest nerves are usually affected first, so symptoms commonly begin in the feet and lower legs before involving the hands. High-arched feet, difficulty lifting the front of the foot, and recurrent ankle instability are characteristic, although the age of onset and degree of disability vary widely.
CMT is not a single disease with one molecular cause. It encompasses disorders produced by pathogenic variants in many different genes, affecting either the insulating myelin sheath around peripheral nerve fibers, the nerve fibers themselves, or both. Most forms affect both motor and sensory nerves. Related inherited disorders predominantly affecting motor or sensory nerves overlap with CMT but are not always classified within it.
Its importance lies in its frequency among inherited neuromuscular disorders, its lifelong effects on mobility and hand function, and its role in revealing how peripheral nerves are maintained. Molecular diagnosis increasingly distinguishes conditions that look similar clinically but have different inheritance patterns, complications, and potential therapeutic targets.
Historical recognition and epidemiology
The disease takes its name from Jean-Martin Charcot, Pierre Marie, and Howard Henry Tooth. In 1886, Charcot and Marie in France and Tooth in England independently described a hereditary disorder with progressive muscular wasting, particularly in the lower legs. Tooth’s work emphasized that the primary abnormality lay in peripheral nerves rather than in muscle or the spinal cord. The historical name “peroneal muscular atrophy” reflects the conspicuous wasting of muscles in the lower leg, although the condition is neither confined to those muscles nor primarily a muscle disease.
During the twentieth century, clinical examination, nerve conduction testing, and nerve biopsy established that similar outward appearances could arise from different pathological processes. Some families had strikingly slow conduction along peripheral nerves and abnormalities of myelin. Others had relatively preserved conduction speed but loss of nerve fibers. These observations provided the basis for the distinction between demyelinating and axonal CMT, later supplemented by intermediate forms. Molecular discoveries beginning in the early 1990s transformed this physiological classification into a genetically defined collection of disorders.
CMT is often described as affecting approximately 1 in 2,500 people, equivalent to about 40 per 100,000. This widely quoted figure is an approximation rather than a uniform global rate. Published estimates of prevalence differ substantially because studies use different populations, diagnostic criteria, and methods of case ascertainment. Mildly affected people may never receive a diagnosis, while studies based on specialist clinics may disproportionately capture more severe disease. Some population studies have reported appreciably lower prevalence than the traditional estimate.
The distribution of genetic subtypes also varies geographically. CMT1A, caused by duplication of a region containing PMP22, is the most common single subtype in many studied populations, particularly those of European ancestry. Recessive forms account for a larger proportion of cases in some populations with higher rates of parental relatedness or particular founder variants. Consequently, the genetic distribution in one national registry cannot automatically be generalized to another population.
Reliable epidemiological comparisons require separation of clinically suspected CMT from molecularly confirmed disease. They also require attention to disorders formerly grouped under broad historical labels. A person with mild high arches and reduced ankle reflexes may be counted in a family study but remain unidentified in routine health records. Conversely, an acquired neuropathy can resemble CMT. These issues affect estimates of disease burden, the composition of research cohorts, and interpretation of diagnostic success rates.
Peripheral nerve biology and mechanisms of injury
Peripheral nerves contain axons, the long cellular extensions through which neurons transmit signals. Motor axons connect the spinal cord to muscles, while sensory axons carry information about touch, vibration, position, temperature, and other stimuli. Many larger axons are surrounded by myelin produced by Schwann cells. Myelin permits rapid electrical conduction by organizing current flow between gaps called nodes of Ranvier. CMT can originate in the axon, the Schwann cell, or the communication between them.
In demyelinating CMT, abnormalities of myelin formation or maintenance slow nerve conduction. Repeated injury and repair may produce “onion bulbs”: concentric layers of Schwann-cell processes and connective tissue around nerve fibers. These structures are characteristic of chronic remodeling but are not specific to CMT. Some genetic forms instead produce unusually thin myelin, focal excessive myelin folding, or severe failure of normal myelination from early life. Thus, the label demyelinating includes several distinct biological processes rather than one uniform lesion.
Axonal CMT primarily impairs the integrity or function of the axon. Long axons have substantial requirements for intracellular transport, energy production, membrane organization, and the delivery of proteins and organelles over considerable distances. Disease-associated genes therefore include those involved in mitochondrial dynamics, cytoskeletal organization, vesicle transport, and RNA processing. For example, MFN2 encodes mitofusin 2, a protein involved in mitochondrial fusion and other aspects of mitochondrial organization. Pathogenic variants can impair the maintenance of long peripheral axons.
The clinical pattern is usually length-dependent. Axons supplying the feet are among the longest in the body and are often affected before those supplying the hands. Loss of motor axons leads to denervation of muscle fibers, compensatory enlargement of surviving motor units, and eventually weakness and muscle wasting. Sensory axon dysfunction reduces protective sensation and position sense, contributing to instability. Muscle itself undergoes secondary structural change, including fatty replacement, rather than being the primary site of the inherited defect.
The distinction between myelin disease and axonal disease is useful but incomplete. Schwann cells provide metabolic and structural support to axons, so a primary myelin abnormality can ultimately cause axonal degeneration. In many demyelinating forms, the extent of axonal loss is more closely related to disability than conduction slowing alone. Conversely, primary axonal abnormalities can alter interactions with Schwann cells. This interdependence explains why a genetic defect in one cellular compartment can produce abnormalities throughout the nerve–muscle system.
Genetic causes, inheritance, and classification
CMT can follow autosomal dominant, autosomal recessive, or X-linked inheritance. In autosomal dominant disease, one pathogenic copy of a gene can be sufficient to cause the disorder; an affected heterozygous parent generally has a 50% probability of transmitting that variant in each pregnancy. In autosomal recessive disease, pathogenic variants affect both copies of the relevant gene. When both parents are carriers of variants in the same recessive disease gene, each pregnancy has a 25% probability of an affected child. These probabilities describe inheritance of the genotype, not the eventual severity of symptoms.
CMT1A usually results from a duplication of approximately 1.4 million base pairs on chromosome 17p11.2 that includes PMP22. The discovery of this duplication in 1991 was a major milestone in understanding human gene-dosage disorders. Increased dosage of PMP22, which encodes peripheral myelin protein 22, disrupts Schwann-cell biology and myelin maintenance. Deletion of the corresponding region usually causes the related but distinct hereditary neuropathy with liability to pressure palsies, characterized by susceptibility to focal nerve dysfunction after pressure or stretching.
Other important genes include MPZ, encoding myelin protein zero; GJB1, encoding connexin 32; and MFN2. GJB1-related disease, commonly called CMTX1, is X-linked. Males are often more severely affected than heterozygous females, although females can have clinically important neuropathy. A male with a GJB1 pathogenic variant transmits it to all daughters and no sons. Clinical differences among females partly reflect X-chromosome inactivation. De novo variants can occur, so an apparently unaffected family does not exclude a genetic neuropathy.
Traditional classification combines inheritance, electrophysiology, and historical numbering. CMT1 generally denotes demyelinating disease, whereas CMT2 denotes predominantly axonal disease. CMTX identifies X-linked forms, and CMT4 has historically grouped autosomal recessive demyelinating forms. Intermediate CMT describes conduction characteristics between conventional demyelinating and axonal ranges. These categories are imperfect: variants in the same gene can cause different electrophysiological patterns, ages of onset, or severity. Gene-based descriptions, such as MPZ-related neuropathy, are therefore often more informative than a subtype label alone.
The effects of a pathogenic variant may involve reduced gene function, an abnormal toxic protein, altered protein interactions, or excessive gene dosage. Even within one family, severity can differ because of age, background genetic variation, and other influences. A molecular finding is not automatically diagnostic: a variant of uncertain significance lacks sufficient evidence to establish causation. Interpretation depends on the clinical pattern, inheritance, population frequency, and laboratory evidence, sometimes including whether the variant segregates with disease in a family.
Clinical manifestations and phenotypic variation
The typical presentation is a slowly progressive, broadly symmetrical distal neuropathy beginning in childhood or adolescence. Early manifestations include frequent tripping, difficulty running, recurrent ankle sprains, and inability to walk on the heels. Weakness of ankle dorsiflexion causes foot drop, sometimes compensated for by a high-stepping gait. Wasting of the lower legs can produce a characteristic tapering appearance. Some people first come to attention because of foot shape rather than an obvious loss of strength.
High-arched feet, or pes cavus, and clawed toes arise through chronic imbalance among muscle groups and changes in soft tissues. Hindfoot varus may accompany the high arch. These deformities can become fixed over time, altering weight distribution and causing pressure areas, calluses, and difficulty fitting footwear. However, high arches are not universal, and some affected children initially have flat feet. A foot deformity alone does not establish CMT because similar shapes occur in other neurological disorders and in people without neuropathy.
Sensory involvement commonly includes reduced vibration perception, impaired joint-position sense, and diminished sensation in the feet. Ankle tendon reflexes are often reduced or absent, with more widespread reflex loss in some subtypes. Sensory symptoms may be less prominent than objective sensory loss. Balance can deteriorate when visual cues are reduced because impaired position sense makes it harder to determine foot placement. Burning, tingling, or neuropathic pain can occur, while musculoskeletal pain may arise from deformity, altered gait, and joint loading.
Hand involvement often appears later, with weakness and wasting of intrinsic hand muscles. Tasks requiring pinch strength or fine coordination—such as fastening buttons, handwriting, or manipulating small objects—may become difficult. Fatigue is common but does not necessarily correspond directly to measured strength. Scoliosis, hip abnormalities, and tremor occur in some individuals. These associated features vary with genotype and severity and are not required for the diagnosis.
Certain subtypes have additional manifestations. Some MFN2-related neuropathies include optic atrophy; some forms involve hearing loss, vocal-fold dysfunction, or respiratory muscle weakness. GJB1-related disease can occasionally produce transient central neurological episodes with reversible white-matter abnormalities. Such findings are exceptions to the predominantly peripheral pattern, rather than defining features of CMT generally. Marked autonomic involvement, severe early ulceration, prominent spasticity, or substantial cognitive impairment may indicate a specific complex genetic syndrome or a different diagnosis. Clinical interpretation therefore depends on the whole pattern rather than on any single symptom.
Diagnostic evaluation and differential diagnosis
The diagnosis begins with the pattern of weakness, sensory loss, foot deformity, and progression. A detailed medical history establishes the age at onset, early motor development, difficulties with walking or hand tasks, and possible exposures or illnesses that could cause an acquired neuropathy. Family history can reveal relatives with diagnosed neuropathy, unexplained foot surgery, high arches, or longstanding gait difficulty. Its absence is not decisive because disease may be mild, recessively inherited, newly arising, or unrecognized in relatives.
The physical examination assesses distal and proximal strength, muscle bulk, tendon reflexes, sensation, gait, balance, and skeletal alignment. Nerve conduction studies provide a physiological framework. Conventionally, an upper-limb motor conduction velocity below approximately 38 metres per second supports a demyelinating classification, while relatively preserved velocity with reduced response amplitudes supports an axonal classification. Intermediate categories overlap these boundaries. Age, limb temperature, disease severity, and the particular nerve tested influence interpretation; a numerical threshold is not a stand-alone diagnosis.
Inherited demyelinating neuropathies often show relatively uniform slowing across nerves. Acquired inflammatory neuropathies more commonly produce nonuniform abnormalities, conduction block, or temporal dispersion, although exceptions occur in both directions. Needle electromyography can demonstrate chronic denervation and reinnervation. These tests help distinguish peripheral neuropathy from primary muscle disease or a motor-neuron disorder, but electrophysiology usually cannot identify the responsible gene by itself.
Molecular testing may include targeted analysis of the PMP22 duplication or deletion, multigene panels, and broader DNA sequencing. Copy-number analysis is important because not all sequencing approaches reliably detect duplications and deletions. The choice and interpretation of testing depend on the clinical and electrophysiological phenotype. A negative result does not exclude inherited neuropathy: some causal variants are difficult to detect, some genes remain incompletely characterized, and current assays differ in coverage. Reanalysis can sometimes resolve cases as genetic knowledge and laboratory methods develop.
The differential diagnosis includes neuropathies associated with diabetes mellitus, alcohol exposure, nutritional deficiencies such as vitamin B12 deficiency, medications, paraproteinemias, and inflammatory disease. Chronic inflammatory demyelinating polyradiculoneuropathy is an important potentially treatable mimic. Hereditary transthyretin amyloidosis can resemble axonal CMT but has a different systemic and therapeutic context. Rapid deterioration, substantial asymmetry, or unexpected systemic findings can indicate an additional or alternative disorder. Nerve biopsy, once central to classification, is now generally reserved for selected unresolved cases, particularly when vasculitis, amyloid deposition, or another tissue-defined process is under consideration.
Natural history, disability, and prognosis
CMT most often progresses over years or decades, but there is no single natural history applicable to all subtypes. Some individuals have only subtle foot deformity and remain independently mobile throughout life. Others develop substantial limitations in childhood. Severe early-onset neuropathies can delay walking or cause major motor disability, whereas some axonal forms do not become apparent until adulthood. The genotype provides useful information about likely patterns, but considerable variation remains within many genetic categories.
In CMT1A, conduction slowing is generally established relatively early and may change little compared with the gradual accumulation of functional impairment. Disability is more closely related to loss of functioning axons, muscle weakness, and secondary musculoskeletal changes than to conduction speed alone. This distinction matters when interpreting follow-up testing: a stable nerve conduction velocity does not necessarily mean that walking ability, balance, or hand function has remained unchanged.
Functional consequences reflect the interaction of neurological impairment with skeletal mechanics and environmental demands. Mild dorsiflexion weakness may produce disproportionately frequent falls on uneven ground. A fixed foot deformity may limit walking even when residual muscle strength is relatively good. Conversely, suitable equipment and accessible environments can reduce activity limitations without changing the underlying neuropathy. Wheelchair use varies widely; some people use one for long distances while retaining the ability to walk shorter distances.
Life expectancy is usually not substantially shortened in the common uncomplicated forms. This does not imply that every genetic subtype is benign. Severe respiratory involvement, vocal-fold dysfunction, or complex multisystem disease can alter outcomes in particular forms. The extent of respiratory impairment cannot be inferred simply from the presence of distal leg weakness. Similarly, an abrupt decline is not the expected course of a typical slowly progressive CMT phenotype and may reflect a superimposed illness or another mechanism.
Measures of health-related quality of life capture effects not fully represented by muscle testing, including pain, fatigue, sleep disturbance, participation, and emotional burden. Educational and occupational consequences depend partly on accessibility and the physical demands of daily tasks. Longitudinal studies therefore distinguish impairment, activity limitation, and participation rather than treating them as interchangeable measures of severity. The prognosis for an individual is informed by genotype, age, observed progression, complications, and functional status; neither a subtype name nor a single examination can determine a precise future level of disability.
Rehabilitation, orthopedic care, and symptomatic management
Clinical care primarily addresses function, deformity, symptoms, and complications. There is no single curative treatment applicable to all forms of CMT. Multidisciplinary care can involve neurology, physical medicine and rehabilitation, orthopedics, physiotherapy, occupational therapy, orthotics, and genetics. The evidence supporting individual interventions varies: some are established components of neuromuscular practice, while comparative trials remain limited by small samples, heterogeneous phenotypes, and the slow course of the disease.
Physical therapy interventions studied in CMT include strength training, aerobic conditioning, balance work, and maintenance of joint range. Their purposes differ: conditioning addresses exercise capacity, whereas stretching targets soft-tissue restriction and strengthening addresses muscles with remaining motor capacity. Clinical research does not support treating all physical activity as harmful, but neither does it establish one exercise regimen for every genotype or severity level. Fixed skeletal deformity, severe weakness, and balance impairment change the mechanical demands of an activity.
Ankle–foot orthoses are used to compensate for foot drop, improve clearance during walking, and provide ankle stability. Different designs alter ankle movement, energy expenditure, and pressure distribution in different ways. Foot orthoses and adapted footwear address alignment and loading, while walking aids and other assistive technologies can improve mobility. Occupational therapy addresses hand function, task modification, splints, equipment, and participation in domestic, educational, and occupational activities. These interventions compensate for impairments rather than correcting the molecular cause.
Orthopedic surgery can address selected painful, unstable, or functionally limiting deformities. Procedures include tendon transfers to rebalance muscle forces, osteotomies to realign bones, and fusion of selected joints in rigid deformity. The choice depends on flexibility, muscle strength, alignment, age, and previous procedures. Surgery changes biomechanics but does not stop neuropathy, so subsequent progression and recurrent deformity remain possible. Outcomes are consequently assessed through pain, alignment, stability, footwear tolerance, and function rather than through correction of nerve conduction abnormalities.
Symptom management distinguishes neuropathic pain from pain caused by joints, tendons, pressure points, or altered gait. Respiratory and vocal-fold complications require subtype- and symptom-specific assessment when present. Medication safety is also relevant: vincristine can cause severe neurotoxicity in people with CMT, an especially important interaction in cancer treatment. Genetic counseling explains inheritance, the limits of predictive testing, and reproductive testing options when a familial pathogenic variant is known. Prenatal and preimplantation genetic testing can identify a familial variant but usually cannot predict the precise severity of the future phenotype.
Therapeutic research and measurement of disease change
CMT research increasingly treats the genetic subtype as the starting point for therapeutic development. A strategy appropriate for excessive PMP22 dosage may not suit a recessive disorder caused by loss of another protein. Likewise, replacing a missing protein differs fundamentally from suppressing a toxic mutant protein. Studies therefore separate molecular mechanisms rather than assuming that every intervention should work across the entire CMT spectrum.
For CMT1A, experimental approaches include reducing PMP22 expression using antisense oligonucleotides, RNA-interference strategies, or related methods. The objective is to bring expression closer to a functional range, not to eliminate the protein: insufficient PMP22 dosage also causes neuropathy. Delivery to Schwann cells, the duration of suppression, immune responses, and control over dose are major translational challenges. Gene therapy is also being investigated for selected loss-of-function subtypes, with the additional challenge of reaching widely distributed peripheral nerves.
Other strategies target shared downstream processes such as axonal maintenance, mitochondrial function, protein handling, and metabolic support. Preclinical studies use cultured cells, patient-derived cellular models, and genetically modified animals. These models can demonstrate biological activity but do not establish benefit in humans. The history of ascorbic acid research illustrates the distinction: promising findings in a mouse model of CMT1A were followed by human randomized trials that did not demonstrate the anticipated clinical benefit.
Clinical studies require outcome measures sensitive enough to detect slow change. The CMT Neuropathy Score combines symptoms, examination findings, and electrophysiological measures; modified examination-based versions are also used. The CMT Pediatric Scale addresses childhood function, where normal growth and motor development complicate interpretation. Walking tests, hand-function measures, and patient-reported outcomes capture complementary aspects of disease. A statistically detectable change in one measure does not automatically establish a meaningful improvement in everyday life.
Potential biomarkers include quantitative muscle magnetic resonance imaging, which can measure fatty replacement, and circulating proteins associated with axonal injury. Their value depends on reproducibility, sensitivity to change, and relationship to clinically important outcomes. A biomarker may be useful for tracking biological activity without being a validated surrogate endpoint for treatment benefit. Randomized controlled trials face additional difficulties because genetic heterogeneity, age, baseline severity, and slow progression can obscure treatment effects. Genetically defined cohorts, longitudinal natural-history data, and appropriate functional endpoints are therefore central to determining whether a candidate treatment changes the course of a specific form of CMT.